Engaging Experts by Journal of Clinical Pathways: Recent Episodes
JCP
Listen along as Journal of Clinical Pathways engages with guest speakers of all variety of expertise to discuss topics related to clinical pathways and value-based care.
Chris Fausel, PharmD, clinical manager, Oncology Pharmacy, Indiana University Health, Val R Adams, PharmD, associate professor, University of Kentucky, Kirollos Hanna, PharmD, oncology pharmacy manager, M Health Fairview—Maple Grove, and assistant professor of Pharmacy, Mayo Clinic College of Medicine, and Lisa Holle, PharmD, clinical professor, UConn School of Pharmacy, UConn Health Carole and Ray Neag Comprehensive Cancer Center, return to discuss Great Debates & Updates Oncology Pharmacy, a CPE event aimed at educating pharmacists interested in oncology developments. In this podcast, the cochairs review last year's program and share what attendees can expect to learn at the meeting in 2022.
David Bond, MD, The Ohio State University Comprehensive Cancer Center (Colombus) discusses results from a study assessed real-world clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era.
Peter Martin, MD, Weill Cornell Medicine (New York, NY), discusses the data that led to the recent accelerated approval of zanubrutinib for the treatment of patients with mantle cell lymphoma.
Michael Birrer, MD, PhD, director of the Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, discusses the latest PARP inhibitor indications for frontline maintenance in ovarian cancer, as well as the impending results of other PARP inhibitor studies in the ovarian space.
Barbara Goff, MD, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses a project she is co-leading on patient-centered education and support for women with advanced ovarian cancer. The research project was one of four that was selected to receive NCCN support and is intended to be reproducible, scalable, and implementable across practices in the US.
Anne-Sophie Darlington, MA, PhD, and Andrew Bottomley, PhD, both with EORTC, provide perspective on how quality of life is regarded by providers and patients today, training needed for clinicians to be better equipped for quality-of-life conversations with patients, and how quality of life can fit into clinical pathways and clinical-decision support tools.
Anne Hubbard, MBA, American Society for Radiation Oncology, discusses updates on CMS’ mandatory radiation alternative payment model, inclusion of radiation therapy in the Oncology Care First model, and other topics at the ACCC Annual Meeting and Cancer Center Business Summit (March 4-6, 2020; Washington, DC).
Thomas Krivak, MD, Allegheny Health Network, lists the PARP inhibitor-based ovarian cancer clinical trials that are worth monitoring other than PRIMA that could change the standard of care for patients with poor prognosis considering maintenance therapy.
Thomas Krivak, MD, Allegheny Health Network, explains the "two schools of thought" for physicians treating high-risk ovarian cancer.
Thomas Krivak, MD, Allegheny Health Network, gives a quick summary of a clinical trial that assessed niraparib in the frontline setting for high-risk patients with ovarian cancer and numerous poor prognostic factors.
Alan Balch, PhD, chief executive officer, National Patient Advocate Foundation, describes his vision of a “person-centered pathway” wherein patient-specific factors and preferences provide the foundation of a clinical pathway.
Alexander Olawaiye, MD, associate professor of gynecologic oncology, University of Pittsburgh, and Magee-Womens Hospital, University of Pittsburgh Medical Center, contextualizes the results of the PRIMA study and the support for PARP inhibitors in the maintenance and upfront treatment settings of ovarian cancer regardless of germline mutation.
Ray Page, DO, PhD, FACOI, FASCO, president and director of research, The Center for Cancer and Blood Disorders, explains the inherent patient-centered nature of clinical pathways at his institution as well as the ability of real-world evidence and artificial intelligence tools to further personalize care.
Edward S Kim, MD, chair of the department of solid tumor oncology, Levine Cancer Institute (Charlotte, NC), shares how patient perspectives and care are regarded as paramount in their in-house clinical pathway program: EAPathways.
Yale Cancer Center’s Kerin Adelson, MD, chief quality officer, and Dena Schulman-Green, PhD, gerontologist and palliative care researcher, discuss the patient-centered considerations within day-to-day cancer care operations and within their clinical pathways.
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with newly-diagnosed ovarian cancer.
Lili Brillstein, MPH, founder and CEO of BCollaborative, describes her background building value-based care models with providers, the growing relationship between providers and health plans as "collaborative partners," and how episodes of care are supported by the development of comprehensive, multidisciplinary clinical pathways.
James L Gajewski, MD, MACP, provides an in-depth breakdown of MACRA assumptions, including common misconceptions and mistakes often made by practices regarding claims data, episodes-of-care classification, and documentation.
Adil Akhtar, MD, provides a commentary on assumptions surrounding palliative care in the US among oncology patients and caregivers, as well as unique efforts employed at Michigan Health Professionals to counteract these assumptions.
At the ASCO Annual Meeting, Journal of Clinical Pathways sat down with Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, president of ACCC, to discuss his goals for his presidency, the common ground between standardized care and patient-centered care, and the role of biosimilars in treating patients with cancer in the immediate future.
Melissa Williams, MPH, manager of health care policy and advocacy, National Patient Advocate Foundation (NPAF), speaks on a new campaign dedicated to improving patient communication with their doctors, as well as the important distinction between patient-centered and person-centered care.
At the ISPOR annual meeting, Journal of Clinical Pathways sat down with a couple of individuals from the University of Colorado who have been tasked with applying and testing novel methods for US health care value assessment.
At the ISPOR Annual Meeting, Journal of Clinical Pathways sat down with the Innovation and Value Initiative team to delve into their latest efforts and involvement in the meeting, including leading discussions and debates on quality-adjusted life-years, value definition and measurement, and a 4-state treatment sequence model for non-small cell lung cancer.
James L Gajewski, MD, MACP, offers a commentary on the pros and cons of physician satisfaction scores, as well as the underlying and inherent dilemma with physician satisfaction scores in cancer care - poor patient compliance to therapy on clinical pathways can result in low scores.
Lee Schwartzberg, MD, FACP, covers a range of topics, including a session he led at the COA Annual Meeting involving the “misguided” practice of step therapy, clinical pathways as a conduit for decreased resource utilization, and his involvement with OneOncology.
At the Community Oncology Alliance (COA) Annual Meeting (April 4-5, 2019; Orlando, FL), Journal of Clinical Pathways sat down with three of the leaders of OneOncology – a new partnership of independent community oncology practices that is physician-driven and utilizes a unified platform to enable physicians to care for patients through the entire course of care. OneOncology was started with three leading community oncology practices: Tennessee Oncology, West Cancer Center, and New York Cancer & Blood Specialists.
At the Association of Community Cancer Centers Annual Meeting and Cancer Center Business Summit, Charles Saunders, MD, chief executive officer, Integra Connect, and Lucio N Gordan, MD, managing physician and president, Florida Cancer Specialists, provided insight on current Oncology Care Model (OCM) performance data and the future of value-based payment modeling post-OCM.
Ray Page, DO, PhD, discusses an artificial intelligence pilot study, conducted at The Center for Cancer and Blood Disorders, to make a positive impact on patient care and decrease inefficiencies in care administration.
James L Gajewski, MD, MACP, provides a background of the two accreditation agencies for hematopoietic cell transplantation centers (AABB and FACT), standards and guidelines they each must abide by, issues in accreditation that often arise, and a look to the future in other countries and disease states.
Dr Gajewski currently serves on the Oregon Medical Association’s board of trustees and is the former president of the Oregon Society of Medical Oncology. He was the founding committee member of both FACT and NCCN’s leukemia and lymphoma clinical guidelines committee.
Journal of Clinical Pathways spoke with Eytan Stein, MD, department of medicine, Memorial Sloan Kettering Cancer Center, regarding an abstract presented at the American Society of Hematology (ASH) Annual Meeting and Exposition (December 1-4, 2018; San Diego, CA) on the activity of enasidenib in previously untreated IDH2-mutant acute myeloid leukemia.
Ravi Vij, MD, MBA, discusses real-world findings related to patients with relapsed or refractory multiple myeloma after daratumumab treatment from a pooled data analysis, PREAMBLE, and the McKesson electronic medical record database.
At the American Society of Hematology (ASH) Annual Meeting and Exposition (December 1-4, 2018; San Diego, CA), Journal of Clinical Pathways spoke with Gunjan L Shah, MD, MS, Memorial Sloan Kettering Cancer Center, regarding how increased use of CAR-T therapy can create challenges in institutional resource capacity and how identifying these resources will allow for better care delivery and allocation of funds.
At the American Society of Hematology (ASH) Annual Meeting and Exposition (December 1-4, 2018; San Diego, CA), Journal of Clinical Pathways spoke with Chadi Nabhan, MD, Cardinal Health, regarding the adverse events, patterns of TLS prophylaxis and management, and dosing patterns in patients with CLL treated in community and academic settings.
At the American Society of Hematology (ASH) Annual Meeting and Exposition (December 1-4, 2018; San Diego, CA), Journal of Clinical Pathways spoke with Loretta J Nastoupil, MD, The University of Texas MD Anderson Cancer Center, regarding the findings of the ZUMA-1 study and their comparability to real-world outcomes in patients with large B-cell lymphoma receiving CAR-T therapy.
Journal of Clinical Pathways spoke with Jennifer Woyach, MD, The Ohio State University Comprehensive Cancer Center, regarding a plenary session at the American Society of Hematology (ASH) Annual Meeting and Exposition (December 1-4, 2018; San Diego, CA) on the activity of ibrutinib in untreated older patients with chronic lymphocytic leukemia (CLL).
Journal of Clinical Pathways spoke with Mohamed Sorror, MD, MSc, Fred Hutchinson Cancer Research Center, regarding the results and larger implications of a study examining survival differences among older patients with AML receiving allogeneic HCT vs non-HCT therapies.